Plant Name: Solanum aculeatissimum
Taxonomic Information:
Plant ID: NPO23754
Plant Latin Name: Solanum aculeatissimum
Taxonomy Genus: Solanum
Taxonomy Family: Solanaceae
Plant External Links:
NCBI TaxonomyDB:
267265
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
IndiaTraditional Medicine System:
Indian Folk; AyurvedaGeographical Distribution:
India
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ACHE; | |
| FLT3; CSNK2A1; | |
| CA7; CA4; CA12; CA9; | |
| ESR2; | |
| NOX4; HSD17B1; HSD17B2; | |
| TYR; | |
| MMP12; | |
| AHR; HIF1A; | |
| THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 8.241E-10 | 1.112E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.132E-09 | 1.112E-05 | CA12, CA4, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.306E-09 | 3.816E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.818E-08 | 1.166E-04 | CA12, CA4, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.105E-07 | 2.057E-04 | CA12, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.134E-07 | 2.057E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.691E-07 | 2.630E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 2.697E-07 | 3.157E-04 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 3.266E-07 | 3.494E-04 | CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FLT3, NOX4, TYR |
| BP | GO:0032502; developmental process | GO:0048513; animal organ development | 1.121E-06 | 9.768E-04 | ACHE, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, FLT3, HIF1A, HSD17B2, TYR |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.248E-06 | 1.045E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.617E-06 | 1.290E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD17B1, HSD17B2, NOX4, TYR |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.659E-06 | 1.290E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 4.619E-06 | 3.244E-03 | AHR, CSNK2A1, HIF1A |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 5.014E-06 | 3.412E-03 | CA9, CSNK2A1, CYP1A1, CYP1A2, FLT3, HSD17B2, TYR |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.104E-06 | 3.909E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 1.475E-05 | 7.845E-03 | ACHE, CSNK2A1, CYP19A1, CYP1A1, HSD17B1, HSD17B2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.981E-05 | 9.585E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.712E-11 | 6.848E-10 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP19A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.198E-09 | 2.288E-08 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.716E-09 | 2.288E-08 | CA12, CA4, CA7, CA9 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 8.252E-06 | 8.252E-05 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.086E-05 | 4.069E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 7.201E-05 | 4.801E-04 | CYP1A2, CYP1A1, CYP1B1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.019E-03 | 5.822E-03 | HSD17B1, HSD17B2, CYP1A2, CYP1A1, TYR, CYP19A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.020E-03 | 8.979E-03 | FLT3, HIF1A |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.903E-03 | 8.979E-03 | CYP1A2, CYP1A1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT3; HIF1A; CA9; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| NA: NA | HIV infections | NA | AHR; |
| C00-D49: Neoplasms | Melanoma | C43 | TYR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| C00-D49: Neoplasms | AML | NA | FLT3; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; FLT3; ACHE; HIF1A; CA9; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | TYR; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; CYP19A1; CA9; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| NA: NA | GIST | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
